| Title |
Treating refractory leukemias in childhood, role of clofarabine
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, April 2008
|
| DOI | 10.2147/tcrm.s2941 |
| Pubmed ID | |
| Authors |
Theresa M Harned, Paul S Gaynon |
| Abstract |
Approximately 4000 children and adolescents under the age of 20 years develop acute leukemia per year in the US. Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Despite impressive improvements in outcome, relapsed ALL is the fourth most common pediatric malignancy. Therapy for relapsed ALL remains unsatisfactory, and the majority of relapse patients still succumb to leukemia. Between one-third and one-half of patients with acute myelogenous leukemia (AML) relapse, and no standard therapy is recognized for patients with relapsed and/or refractory AML. Novel therapeutic agents are needed to improve the cure rate for relapsed ALL and AML. Clofarabine is a next-generation nucleoside analog, designed to incorporate the best features and improve the therapeutic index of cladribine and fludarabine. Clofarabine inhibits both DNA polymerase and ribonucleotide reductase, leading to impaired DNA synthesis and repair, and directly induces apoptosis. Phase I and II single-agent trials in children have shown that clofarabine is safe and active in both myeloid and lymphoid relapsed/refractory acute leukemias. Clofarabine has been approved by the FDA for pediatric patients with relapsed/refractory ALL after at least 2 prior therapeutic attempts. Rational combinations of clofarabine with other active agents in refractory leukemias are currently under investigation. |
Mendeley readers
The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 35 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 20% |
| Other | 4 | 11% |
| Professor > Associate Professor | 3 | 9% |
| Student > Doctoral Student | 3 | 9% |
| Professor | 3 | 9% |
| Other | 11 | 31% |
| Unknown | 4 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 49% |
| Agricultural and Biological Sciences | 5 | 14% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Chemistry | 1 | 3% |
| Unspecified | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 8 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2014.
All research outputs
#5,446,210
of 25,371,288 outputs
Outputs from Therapeutics and Clinical Risk Management
#275
of 1,323 outputs
Outputs of similar age
#18,648
of 95,969 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 13 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,969 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.